We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current LAB market cap is 707.29M. The company's latest EPS is USD -0.2005 and P/E is -18.50.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 25.37M | 28.19M | 45.54M | 37.21M | 44.97M |
| Operating Income | -21.17M | -21.39M | -60.18M | -50.52M | -31.72M |
| Net Income | -21M | -19.78M | -78.17M | -45.72M | -26.94M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 117.24M | 138.14M | 130.58M | 97.95M | 106.34M |
| Operating Income | -51.84M | -51.04M | -67.46M | -116.21M | -76.6M |
| Net Income | -64.79M | -53.02M | -59.24M | -190.1M | -74.66M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 339.29M | 323.07M | 777.67M | 708.73M | 681.54M |
| Total Liabilities | 159.75M | 159.87M | 200.35M | 198.47M | 192.21M |
| Total Equity | -131.72M | -148.05M | 577.32M | 510.26M | 489.33M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 264.81M | 324.76M | 275.21M | 390.31M | 323.07M |
| Total Liabilities | 111.2M | 185.71M | 180.62M | 160.52M | 159.87M |
| Total Equity | 153.61M | 139.05M | 94.6M | -81.47M | -148.05M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -29.23M | -43.29M | -62.48M | -101.53M | -129.4M |
| Investing | 33.35M | 20.24M | 318.08M | 368.33M | 337.45M |
| Financing | -5.81M | -6.81M | -19.73M | -48.09M | -48.1M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -35.21M | -15.42M | -44.06M | -89.37M | -43.29M |
| Investing | -39.3M | 39.98M | -11.95M | -88.13M | 20.24M |
| Financing | 2.79M | 20.86M | 15.96M | 230.76M | -6.81M |
| Market Cap | 707.29M |
| Price to Earnings Ratio | -18.50 |
| Price to Sales Ratio | 12.99 |
| Price to Cash Ratio | 26.71 |
| Price to Book Ratio | 8.46 |
| Dividend Yield | - |
| Shares Outstanding | 372.26M |
| Average Volume (1 week) | 1.51M |
| Average Volume (1 Month) | 1.42M |
| 52 Week Change | -9.95% |
| 52 Week High | 3.04 |
| 52 Week Low | 1.21 |
| Spread (Intraday) | 1.2 (46.15%) |
| Company Name | Standard BioTools Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.fluidigm.com |
| Industry | lab analytical instruments (3826) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
